E

Europejskie Centrum Zdrowia Otwock | Onkologia

Research site

(Unclaimed)

Location

Borowa 14/18, Otwock, Mazovia, Poland

Site insights

Top conditions

Top treatments

Cisplatin

Pembrolizumab

Palbociclib

MK-3475-866

MK-7902

L-DOS47

Letrozole

Enfortumab

PD-0332991

MK-3475-905

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 8 total trials

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible o...

Active, not recruiting

Urinary Bladder Cancer, Muscle-invasive

Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])

Drug: Pembrolizumab

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible pat...

Active, not recruiting

Bladder Cancer

Drug: Placebo

Drug: Pembrolizumab